Skip to main content
!
Phase III+: The University is open for expanded research operations; only authorized personnel will be admitted on campus. More info here.

Women & Science Entrepreneurship Fund Speaker Series


Pathways in Bioscience: Four Perspectives Beyond the Bench


Thursday, December 2, 2021
4:00 – 5:00 PM ET
Live Webinar


Leigh Baxt TDI headshot

Panelist

Leigh Baxt, Ph.D.
Associate Director of Biology
Tri-Institutional Therapeutics Discovery Institute

Leigh Baxt has been an Associate Director of Biology at the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) since 2018. The Tri-I TDI is a collaboration between Rockefeller University, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and biopharmaceutical partner Takeda. The mission of the TDI is to encourage researchers in the Tri-I community to advance groundbreaking biological discoveries to preclinical studies. In her role, Dr. Baxt provides strategic and technical guidance for steps ranging from target validation, assay selection and development to animal proof-of-concept studies.

A key contributor to multiple commercially licensed programs, Dr. Baxt has experience with strategic aspects of early small molecule drug discovery for a wide variety of disease areas and has worked on more than 30 early discovery programs.

Dr. Baxt received a B.A. in biology from Brown University and a Ph.D. in microbiology and immunology from Stanford University School of Medicine. She completed a postdoctoral fellowship at Massachusetts General Hospital and Harvard Medical School, and was a research scientist at the Broad Institute.